Since ILK or IPP is highly upregulated in multiple diseases, such as cancer, diabetes, and heart failure5,7,15,17,18, our findings also open the door for developing unique therapeutic inhibitors of ILK, not as a kinase, but as a pseudokinase, by targeting at its Mg-ATP site or its binding to other proteins. This evidence concerns the gene ILK and diabetes mellitus.